Quarterly report pursuant to Section 13 or 15(d)

Research and Development Agreements - Additional Information (Detail)

v3.21.2
Research and Development Agreements - Additional Information (Detail) - USD ($)
$ / shares in Units, $ in Thousands
1 Months Ended 3 Months Ended 6 Months Ended 107 Months Ended
Feb. 28, 2021
Nov. 30, 2019
Sep. 30, 2018
Jun. 30, 2021
Jun. 30, 2020
Mar. 31, 2020
Jun. 30, 2021
Jun. 30, 2020
Nov. 30, 2019
Dec. 31, 2020
Research And Development Collaboration Agreements [Line Items]                    
Research and development revenue recognized       $ 15,134 $ 6,040   $ 18,354 $ 7,840    
Common stock, shares issued       56,138,404     56,138,404     49,984,333
Common stock, par value       $ 0.001     $ 0.001     $ 0.001
Revenue from grant       $ 15,134 6,909   $ 18,354 11,050    
Grant Agreements | Grants Revenue Receivable                    
Research And Development Collaboration Agreements [Line Items]                    
Reimbursement amounts submitted in excess of amounts received are recorded as receivables       0     0     $ 0
Grant                    
Research And Development Collaboration Agreements [Line Items]                    
Revenue from grant       0 $ 869   0 $ 3,210    
Takeda Pharmaceuticals Inc                    
Research And Development Collaboration Agreements [Line Items]                    
Deferred revenue, current       0     0     789
Deferred revenue, non-current       2,586     2,586     3,106
Cancer Prevention and Research Institute of Texas | CPRIT Agreement                    
Research And Development Collaboration Agreements [Line Items]                    
Product development grant awarded     $ 15,200              
Cancer Prevention and Research Institute of Texas | ETB MT-3724 | CPRIT Agreement                    
Research And Development Collaboration Agreements [Line Items]                    
Aggregate proceeds received from award granted                 $ 10,600  
Revenue from grant             20,000      
Grants Receivable       0     0      
Takeda Development Agreement                    
Research And Development Collaboration Agreements [Line Items]                    
Total transaction price             29,800      
Upfront payment             30,000      
Development milestone payment that is achievable           $ 10,000        
Expected co-share payments payable       10,200     10,200      
Research and development revenue recognized       12,900            
Deferred revenue       0     0     1,300
Takeda Multi Target Agreement | Takeda Pharmaceuticals Inc                    
Research And Development Collaboration Agreements [Line Items]                    
Deferred revenue       2,600     2,600     2,600
Cumulative payments received             5,000      
Aggregate milestone payments upon exercise of option to license ETBS       30,000     30,000      
Milestone payments receivable if option is exercised             397,000      
Takeda Multi Target Agreement | Takeda Pharmaceuticals Inc | Maximum                    
Research And Development Collaboration Agreements [Line Items]                    
Contractual contingency fees             10,000      
Commercial milestone payment             150,000      
Vertex Collaboration Agreement                    
Research And Development Collaboration Agreements [Line Items]                    
Upfront payment   $ 38,000                
Milestone payments receivable if option is exercised   180,000                
Upfront payment, cash   23,000                
Upfront payment, equity method investments   $ 15,000             $ 15,000  
Deferred revenue, current       12,800     12,800     13,900
Deferred revenue, non-current       3,300     3,300     $ 4,500
Common stock, shares issued   1,666,666             1,666,666  
Common stock, par value   $ 0.001             $ 0.001  
Vertex Collaboration Agreement | Common Stock                    
Research And Development Collaboration Agreements [Line Items]                    
Purchase price per share   $ 9.00             $ 9.00  
Fair value of allocated consideration   $ 4,500                
Vertex Collaboration Agreement | Sales Milestone                    
Research And Development Collaboration Agreements [Line Items]                    
Milestone payments receivable if option is exercised   70,000                
Vertex Collaboration Agreement | ETBs                    
Research And Development Collaboration Agreements [Line Items]                    
Aggregate milestone payments upon exercise of option to license ETBS   $ 22,000             $ 22,000  
Bristol Myers Squibb Collaboration Agreement                    
Research And Development Collaboration Agreements [Line Items]                    
Upfront payment $ 70,000                  
Milestone payments receivable if option is exercised 874,500                  
Deferred revenue, current       17,800     17,800      
Deferred revenue, non-current       $ 49,200     $ 49,200      
Transaction price allocated to performance obligations 70,000                  
Bristol Myers Squibb Collaboration Agreement | Sales Milestone                    
Research And Development Collaboration Agreements [Line Items]                    
Milestone payments receivable if option is exercised $ 450,000